Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.48 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 5/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.42 |
| ▸ | FABP3 | P05413 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032620 | 0.98 | LPAR3 (0.50) | LPAR3GGPS1LPAR2TSHRFDPS | |
| SCHEMBL703313 | 0.98 | LPAR3 (0.50) | LPAR3GGPS1LPAR2TSHRFDPS | |
| SCHEMBL699777 | 0.98 | LPAR3 (0.50) | LPAR3GGPS1LPAR2TSHRFDPS | |
| SCHEMBL6626608 | 0.92 | — | — | |
| SCHEMBL103934 | 0.81 | — | — | |
| SCHEMBL2987160 | 0.76 | LPAR3 (0.55) | LPAR3GGPS1LPAR2LPAR1FABP3 | |
| SCHEMBL27865664 | 0.75 | LPAR2 (0.33) | LPAR3LPAR2TSHRLPAR1 | |
| Phosphoric Acid SCHEMBL3911255 | 0.75 | LPAR3 (0.64) | LPAR3GGPS1LPAR2LPAR1FABP3 | |
| Phosphoric Acid SCHEMBL11225058 | 0.75 | LPAR3 (0.64) | LPAR3GGPS1LPAR2LPAR1FABP3 | |
| SCHEMBL18864277 | 0.75 | LPAR3 (0.53) | LPAR3GGPS1LPAR2LPAR1FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363317-B2 | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | ONXEO (FR) | 2019-07-30 | — | — | US | disclosed |
| EP-1657286-B1 | Radiation curable ink jet ink, comprising a polymerisation initiation sensitising dye | FUJIFILM CORP (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-1859954-B2 | Planographic printing plate precursor and stack thereof | FUJIFILM CORP (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-2042921-B1 | Pigment dispersion composition, photocurable composition and color filter | FUJIFILM CORP (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-20170298089-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | VALERIO THERAPEUTICS (FR) | 2017-10-19 | — | — | US | disclosed |
| EP-2006738-B1 | Lithographic printing plate precursor | FUJIFILM CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9687557-B2 | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | ONXEO (FR) | 2017-06-27 | — | — | US | disclosed |
| US-9557643-B2 | Pattern forming method, actinic ray-sensitive or radiation-sensitive resin composition, resist film, manufacturing method of electronic device using the same and electronic device | FUJIFILM CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2252584-B1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160339107-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | VALERIO THERAPEUTICS (FR) | 2016-11-24 | — | — | US | disclosed |
| EP-0949540-A1 | Method for producing lithographic printing plate suitable for laser scan exposure, and photopolymerizable composition | FUJI PHOTO FILM CO., LTD (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0945264-A1 | Anionic infrared-ray absorbing agent, photosensitive composition and planographic printing plate precursor using same | FUJI PHOTO FILM CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0938972-A1 | Photosensitive lithographic form plate using an image-forming material | FUJI PHOTO FILM CO., LTD. (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0924570-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0922570-A2 | Planographic printing plate precursor and a method for producing a planographic plate | Fuji Photo Film Co., Ltd. (JP) | 1999-06-16 | — | — | EP | disclosed |
| US-5837748-A | THIAZOLYLIDENE DERIVATIVE PHOTOINITIATOR; VISIBLE LIGHT PHOTOSENSITIVITY; PRINTING PLATES | FUJI PHOTO FILM CO., LTD. (JP) | 1998-11-17 | — | — | US | disclosed |
| EP-0860741-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1998-08-26 | — | — | EP | disclosed |
| US-5721288-A | FOR UNSATURATED COMPOUNDS | FUJI PHOTO FILM CO., LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0726497-A2 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0726498-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339107-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | EEA1, RNASE1, ASGR1 | LPAR3 1018/4885GGPS1 2790/4885LPAR2 980/4885 |
| US-20170298089-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | EEA1, RNASE1, ASGR1 | LPAR3 1018/4885GGPS1 2790/4885LPAR2 980/4885 |
| US-10363317-B2 | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | EEA1, RNASE1, ASGR1 | LPAR3 1018/4885GGPS1 2790/4885LPAR2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.